TROPION-Lung01 Study Design and Baseline demographics

Response and Interim OS Response Rate 45 40 10 525322505 15 ORR Complete response (0.5%) • 36.4% Partial response ORR 22.9% ° Patients with response, % *Information fraction: 39%. Dato-DXd ICC (n=365) (n=367) ORR, confirmed objective response rate by BICR OS: Dual Primary Endpoint OS data not mature:* Median follow-up 9.7 months A trend favouring Dato-DXd was observed: — HR 0.84 (95% CI 0.62-1.14) • The study is continuing to the next planned analysis for OS 32 Daiichi-Sankyo

View entire presentation